来那度胺联合VAD方案治疗多发性骨髓瘤患者的临床疗效及安全性

Clinical Efficacy and Safety of Lenalidomide Combined with VAD Regimen in Patients with Multiple Myeloma

目的:探讨来那度胺联合VAD方案治疗多发性骨髓瘤患者的临床疗效及安全性。方法:选取2018年5月至2020年5月期间于南阳市第二人民医院治疗的86例多发性骨髓瘤患者为研究对象,随机分为观察组和对照组,各43例,对照组采用VAD方案进行治疗,观察组在对照组的基础上加用来那度胺胶囊。比较两组患者的临床疗效、治疗前后的血红蛋白(HGB)及白蛋白(Alb)以及骨髓浆细胞比率、不良反应发生率。结果:观察组患者的治疗总有效率为81.40%,较对照组的60.47%更高,差异具有统计学意义(P<0.05);治疗4个月后,与治疗前相比,两组患者的骨髓浆细胞比率均明显下降,HGB及Alb均明显上升,而观察组骨髓浆细胞比率低于对照组,HGB及Alb高于对照组,差异均具有统计学意义(P<0.05);两组患者治疗期间的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:来那度胺联合VAD方案治疗多发性骨髓瘤患者的临床效果较单一VAD方案治疗更佳,且安全性较高。

Objective To investigate the clinical efficacy and safety of lenalidomide combined with VAD in the treatment of multiple myeloma.Methods 86 patients with multiple myeloma who were admitted to Nanyang Second General Hospital for treatment from May 2018 to May 2020 were selected as the research objects,and randomly divided into observation group and control group,with 43 cases in each group.The clinical efficacy,hemoglobin(HGB)and albumin(Alb)before and after treatment,the ratio of bone marrow plasma cells,and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 81.40%,which was higher than 60.47% of the control group,the difference was statistically significant(P<0.05).After 4 months of treatment,the ratio of marrow plasma cells in the two groups were significantly decreased,and HGB and Alb were significantly increased compared with before treatment,while the ratio of marrow plasma cells in the observation group was lower than that in control group,while HGB and Alb were higher than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion Lenalidomide combined with VAD has a better clinical effect and higher safety than VAD alone in the treatment of multiple myeloma patients.